Witlox, Willem J. A.
Grimm, Sabine E.
Riemsma, Rob
Armstrong, Nigel
Ryder, Steve
Duffy, Steven
Carrera, Vanesa Huertas
Posadzki, Pawel
Worthy, Gillian
Pouwels, Xavier G. L. V.
Ramaekers, Bram L. T.
Kleijnen, Jos
Joore, Manuela A.
van Asselt, Antoinette D. I. http://orcid.org/0000-0001-7705-9906
Funding for this research was provided by:
National Institute for Health and Care Excellence (Health Technology Assessment Programme)
University of Groningen
Article History
Accepted: 15 October 2020
First Online: 4 November 2020
Declarations
:
: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment (HTA) Programme. Please visit the HTA programme website for further project information (ExternalRef removed).
: WW, RR, NA, SR, SD, VHC, PP, GW, XP, BR, JK, MJ, SG, and AvA have no conflicts of interest to declare.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: All authors have commented on the submitted manuscript and have given their approval for the final version to be published. RR, SD, and JK critiqued the clinical effectiveness data reported by the company. VHC and PP critiqued the literature searches undertaken by the company. GW critiqued the statistical analyses performed by the company. WW, NA, SR, XP, BR, MJ, SG, and AvA critiqued the mathematical model provided and the cost-effectiveness analyses submitted by the company. AvA acts as overall guarantor for this article. This article has not been externally peer reviewed by <i>PharmacoEconomics</i>.